Return to Web Version
American Academy of Family Physicians

Cardiovascular Disease


Cardiovascular Disease, Aspirin for Prevention of Men 45 to 79

The AAFP recommends the use of aspirin for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in gastrointestinal hemorrhage. (2009)

(Grade: A recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm

Cardiovascular Disease, Aspirin for Prevention of Women 55 to 79

The AAFP recommends the use of aspirin for women age 55 to 79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage. (2009)

(Grade: A recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm

Cardiovascular Disease, Aspirin for Prevention of Adults younger than 45

The AAFP recommends against the use of aspirin for stroke prevention in women younger than 55 years and for myocardial infarction prevention in men younger than 45 years. (2009)

(Grade: D recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm

Cardiovascular Disease, Aspirin for Prevention of Adults 80 years or older

The AAFP concludes that the evidence is insufficient to assess the benefits and harms of aspirin for cardiovascular disease prevention in men and women 80 years or older. (2009)

(Grade: I recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm

Cardiovascular Disease, Genomic Testing

The AAFP recommends against genomics profiling to assess risk for cardiovascular disease. The net health benefit from the use of any genomic tests for the assessment of cardiovascular disease risk is negligible and there is no evidence that they lead to improved patient management or increased risk reduction. (2012)

Clinical Consideration: http://www.nature.com/gim/journal/v12/n12/pdf/gim2010136a.pdf (5-page PDF. About PDFs)